Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. - Archive ouverte HAL Access content directly
Journal Articles PLoS ONE Year : 2009

Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice.

(1, 2) , (1, 2) , (2) , (1, 2)
1
2

Abstract

BACKGROUND: With the development of new specific inhibitors of hepatitis C virus (HCV) enzymes and functions that may yield different antiviral responses and resistance profiles according to the HCV subtype, correct HCV genotype 1 subtype identification is mandatory in clinical trials for stratification and interpretation purposes and will likely become necessary in future clinical practice. The goal of this study was to identify the appropriate molecular tool(s) for accurate HCV genotype 1 subtype determination. METHODOLOGY/PRINCIPAL FINDINGS: A large cohort of 500 treatment-naïve patients eligible for HCV drug trials and infected with either subtype 1a or 1b was studied. Methods based on the sole analysis of the 5' non-coding region (5'NCR) by sequence analysis or reverse hybridization failed to correctly identify HCV subtype 1a in 22.8%-29.5% of cases, and HCV subtype 1b in 9.5%-8.7% of cases. Natural polymorphisms at positions 107, 204 and/or 243 were responsible for mis-subtyping with these methods. A real-time PCR method using genotype- and subtype-specific primers and probes located in both the 5'NCR and the NS5B-coding region failed to correctly identify HCV genotype 1 subtype in approximately 10% of cases. The second-generation line probe assay, a reverse hybridization assay that uses probes targeting both the 5'NCR and core-coding region, correctly identified HCV subtypes 1a and 1b in more than 99% of cases. CONCLUSIONS/SIGNIFICANCE: In the context of new HCV drug development, HCV genotyping methods based on the exclusive analysis of the 5'NCR should be avoided. The second-generation line probe assay is currently the best commercial assay for determination of HCV genotype 1 subtypes 1a and 1b in clinical trials and practice.
Fichier principal
Vignette du fichier
journal.pone.0008209.pdf (527.36 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

inserm-00443832 , version 1 (04-01-2010)

Identifiers

Cite

Stéphane Chevaliez, Magali Bouvier-Alias, Rozenn Brillet, Jean-Michel Pawlotsky. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice.. PLoS ONE, 2009, 4 (12), pp.e8209. ⟨10.1371/journal.pone.0008209⟩. ⟨inserm-00443832⟩

Collections

INSERM IMRB UPEC
87 View
174 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More